ADMA Biologics Receives $5M Tranche From Hercules Technology Growth Capital
GlobeNewswire - Mon Dec 15, 7:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has received a $5 million tranche from Hercules Technology Growth Capital, Inc. (NYSE:HTGC), the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets. The $5 million was based upon ADMA achieving clinical endpoints of a Phase III clinical study of RI-002 as a treatment for Primary Immunodeficiency Disease (PIDD), under its existing loan and security agreement.
HTGC: 14.11 (-0.40), ADMA: 10.90 (-0.09)
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:30PM CST
ADMA Biologics' (ADMA) RI-002 met the primary endpoint in a late-stage study conducted in patients suffering from primary immune deficiency disease.
BIIB: 325.13 (-10.67), ADMA: 10.90 (-0.09), ANIP: 55.08 (+1.32), AMGN: 159.44 (-0.16)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 04, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RDUS: 26.30 (+1.20), IMDZ: 22.15 (+0.35), ADMA: 10.90 (-0.09), MCEP: 6.16 (+0.66), SCYX: 10.10 (+0.06), BOBE: 49.77 (-0.90), HCCI: 10.44 (+0.35), TCCO: 5.31 (+0.60), STRZB: 28.93 (+0.21), STRZA: 27.85 (-0.64)
ADMA Biologics Slumps: ADMA Tanks 11% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:53AM CST
ADMA Biologics has been witnessing a positive trend in its current year estimate revision and its share price has been falling for past few days
BIIB: 325.13 (-10.67), ADMA: 10.90 (-0.09), ANIP: 55.08 (+1.32), AFFX: 8.90 (+0.10)
ADMA lead product successful in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 11:50AM CST
ADMA: 10.90 (-0.09)
ADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients
GlobeNewswire - Wed Dec 03, 7:10AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.
ADMA: 10.90 (-0.09)
ADMA Biologics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 3:39PM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the Oppenheimer 25 Annual Healthcare Conference at 10:20 AM ET on December 11, 2014 at the Crowne Plaza Hotel in New York City.
ADMA: 10.90 (-0.09)
ADMA Biologics, Inc. (Nasdaq:ADMA) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Tue Nov 25, 9:19AM CST
What:
ADMA: 10.90 (-0.09), NDAQ: 45.74 (-0.72)
ADMA Biologics Opens Plasma Collection Center in Marietta, Georgia
GlobeNewswire - Tue Nov 18, 6:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), today announced the opening of its second plasma collection facility in Marietta, Georgia.
ADMA: 10.90 (-0.09)
ADMA Biologics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:14AM CST
ADMA: 10.90 (-0.09)
ADMA Biologics to Present at the 9th International Respiratory Syncytial Virus (RSV) Symposium
GlobeNewswire - Mon Nov 10, 6:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), announced today that it will be presenting data describing the composition and efficacy in an animal model of its polyclonal IVIG product, RI-002, at the 9th International Respiratory Syncytial Virus (RSV) Symposium, in Cape Town, South Africa. The abstract is titled: "Treatment of Normal and Immune Suppressed Cotton Rats with IVIG Containing High Titer Neutralizing Anti-RSV Antibody."
ADMA: 10.90 (-0.09)
ADMA Biologics Reports Third Quarter 2014 Financial and Operational Results
GlobeNewswire - Mon Nov 10, 6:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported its financial and operational results for the third quarter ended September 30, 2014 and announced recent Company developments and anticipated milestones for the remainder of 2014.
ADMA: 10.90 (-0.09)
ADMA Biologics Approved for Trading on NASDAQ
GlobeNewswire - Wed Nov 05, 3:38PM CST
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that the NASDAQ stock market has approved ADMA's common stock for listing on the NASDAQ Capital Market and is expected to begin trading on November 10, 2014 under the symbol "ADMA."
ADMA: 10.90 (-0.09)
ADMA Biologics to Present "Ascending Company" Presentation at BioNJ CEO Summit
Business Wire - Thu Oct 16, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the BioNJ CEO Summit Conference at 9:30 AM ET on October 21, 2014 at the Bridgewater Marriott, in Bridgewater, New Jersey.
ADMA: 10.90 (-0.09)
ADMA Biologics' Plasma Collection Subsidiary ADMA BioCenters Norcross, GA Facility Expands Global Regulatory Approval Presence
Business Wire - Wed Sep 10, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that its wholly owned subsidiary, ADMA BioCenters in Norcross, Georgia, received approval from the Korean Ministry of Food and Drug Safety (MFDS) for the sale of source plasma into South Korea.
ADMA: 10.90 (-0.09)
ADMA Biologics Reports Second Quarter 2014 Financial and Operational Results
Business Wire - Mon Aug 11, 3:35PM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported its financial and operational results for the second quarter ended June 30, 2014 and announced recent company developments and anticipated milestones for 2014.
ADMA: 10.90 (-0.09)
ADMA Biologics Forms Scientific Advisory Board with Expertise in Immune Deficiencies, Infectious Diseases and Transplantation
Business Wire - Mon Jun 16, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the formation of its Scientific Advisory Board (SAB) with the following appointments: R. Michael Blaese, M.D., Roy F. Chemaly, M.D., M.P.H., John DeVincenzo, M.D., Richard O'Reilly, M.D., Jordan S. Orange, M.D., Ph.D., and E. Richard Stiehm, M.D.
ADMA: 10.90 (-0.09)
ADMA Biologics to Present at 9th Annual JMP Securities Healthcare Conference on June 24
Business Wire - Fri Jun 13, 3:15PM CDT
ADMA Biologics, Inc. (OTCQB: ADMA), a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that Adam Grossman, ADMA's President, Chief Executive Officer and founder, is scheduled to present a company overview at the conference on Tuesday, June 24, 2014 at 12:00 p.m. EDT, at The Westin New York Grand Central Hotel, New York, NY.
ADMA: 10.90 (-0.09)